Japan's Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds - Reuters
Japan's Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"The jury spent five weeks listening to incredibly detailed testimony about patent litigation, FDA regulation and pharmacoeconomics, and they fundamentally understood that paying a competitor to stay out of the market harms competition and harms the American healthcare system."
— Kristen A. Johnson , Executive
Key People
Attorney representing the plaintiffs in the lawsuit against Takeda Pharmaceuticals.
Attorney representing the plaintiff class in the lawsuit against Takeda Pharmaceuticals.
Attorney representing plaintiffs in the antitrust lawsuit against Takeda Pharmaceuticals.
Attorney associated with the plaintiff class in the case against Takeda.
Attorney involved in the class-action lawsuit against Takeda Pharmaceuticals.
Par Pharmaceutical is a company that focused on developing generic and branded pharmaceuticals.
Attorney representing the plaintiff class in the antitrust case against Takeda.
Sucampo Pharmaceuticals is a biopharmaceutical company that developed the constipation drug Amitiza.
Takeda Pharmaceutical is a global research and development-based pharmaceutical company based in Japan.
Lead trial counsel representing the plaintiff class in the antitrust lawsuit against Takeda.
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNaFJSSWFEbGxOWjZyYm1GOVVNWXUtRXBMSnlYXzU5U3BDMlc1ZEpjS1cwbnFoVDR2WHBnQUJGVDU3LVFQRUJkQ2FabWpvSmk0NFFyemtNT3pFY1gzQWlRSzNKbkZSZXdxcWNac3hsel92TjhrN1Ffc0Vld2s2NVBWOWppbEZDTk5oX2lOT1l2eGlLQUxKQWRfeGJmc25ja2FjWGtwcDNVLWhleU0zUDNPRVA0NW5lUWNqZG9r?oc=5" target="_blank">Japan's Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds</a> <font color="#6f6f6f">Reuters</font>
A U.S. jury found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an anticompetitive scheme.
A Boston federal jury found Takeda Pharmaceuticals conspired with a generic drugmaker to delay the launch of a generic version of Takeda's anticonstipation drug, awarding purchasers $885 million, a figure that's expected to swell after a rule tripling plaintiffs' antitrust damages is applied.
A federal jury ordered Takeda Pharmaceuticals Co. Ltd. to pay $884.9 million in damages for violating antitrust law by delaying the generic version of its branded Amitiza drug through an illegal agreement with a competitor.
A Boston jury found Takeda Pharmaceutical responsible for $885 million in damages, ruling they delayed a generic version of Amitiza through an anticompetitive scheme. This marks the first such jury verdict since 2013.
A class-action lawsuit against Takeda Pharmaceuticals USA Inc. on behalf of direct purchasers of Amitiza and its generic equivalents ended today when a jury returned a verdict finding the pharma giant liable for $474.89 million in damages, according to attorneys at Hagens Berman.
Similar Stories
Related coverage based on topic and tags
Halozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters
Halozyme wins court order to block Merck's injected Keytruda in select European markets Reuters
October 7, 2026 at 05:03 PMJapan beer giants raided over alleged price-fixing cartel
Asahi, Kirin and Suntory confirmed their premises were searched by Japanese competition authorities.
October 7, 2026 at 12:09 PMUS states label abortion drugs a 'public nuisance' in bid to curb access - Reuters
US states label abortion drugs a 'public nuisance' in bid to curb access Reuters
October 8, 2026 at 01:24 PMUS FDA approves Asahi Kasei's drug for persistent herpes infections - Reuters
US FDA approves Asahi Kasei's drug for persistent herpes infections Reuters
October 9, 2026 at 06:01 PMUS FDA expands use of Novartis drug for chronic skin condition - Reuters
US FDA expands use of Novartis drug for chronic skin condition Reuters
October 7, 2026 at 04:51 PMPharma lobby sues Trump administration over Medicare drug price cuts - Reuters
Pharma lobby sues Trump administration over Medicare drug price cuts Reuters
October 7, 2026 at 05:08 PM